Accès ouvert
2026
article
OpenAlex
Nikolaj Juul Nitschke, Marwa Almosailleakh, Issa Ismail Issa, Clara Amanda Skov et autres
Germline DDX41 variants are found in up to 4% of patients with acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDSs), with a higher prevalence among males and a late onset. In this study, we analyzed 647 Danish patients with suspected myeloid neoplasms …
dk
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Eileen Wedge, Andreas Ørslev Rasmussen, Line Borgwardt, Jack B. Cowland et autres
Whilst biallelic variants in RTEL1 are an established cause of telomere biology disorder (TBD), the significance of heterozygous variants has been more challenging to establish. In this nationwide analysis, we describe 18 individuals with heterozygous pathogenic RTEL1 variants from seven families. All …
dk
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Maja Zimmer Jakobsen, Emil-August Torp, Issa Ismail Issa, Helle Høholt et autres
High-throughput sequencing is transforming cancer diagnostics, research, and clinical decision-making, yet accurate identification of disease-driving somatic variants often requires comparing tumor and normal DNA. This study aimed to identify the optimal normal reference sample for whole exome sequencing (WES) in myeloid-derived cancers. …
dk
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Hanne Due, Asta Brogaard, Issa Ismail Issa, Maja Zimmer Jakobsen et autres
Numerous clinical trials have attempted to improve first-line R-CHOP treatment of diffuse large B-cell lymphoma (DLBCL) through the addition or substitution of drugs. The REMoDL-B trial, testing the addition of bortezomib (RB-CHOP), revealed that ABC and molecular high-grade DLBCL patients benefit from …
dk
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Waseem Lone, Alyssa Bouska, Tyler A. Herek, Catalina Amador et autres
High-grade B-cell lymphoma not otherwise specified (HGBCL, NOS) has overlapping morphological and genetic features with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), leading to uncertainty in its diagnosis and clinical management. Using functional genomic approaches, we previously characterized HGBCL and …
us, in
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Issa Ismail Issa, Hanne Due, Rasmus Froberg Brøndum, Vidthdyan Veeravakaran et autres
The recurrence of diffuse large B-cell lymphoma (DLBCL) has been observed in 40% of cases. The standard of care for refractory/relapsed DLBCL (RR-DLBCL) is platinum-based treatment prior to autologous stem cell transplantation; however, the prognosis for RR-DLBCL patients remains poor. Thus, to …
dk, se
(code pays fourni par la source)
Accès ouvert
2024
dissertation
OpenAlex
Issa Ismail Issa
Included are four scientific papers and an introduction to drug response mechanisms in diffuse large B-cell lymphoma from the perspective of molecular biology.
dk
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Hanne Due, Issa Ismail Issa, Martin K. Thomsen, Maja Zimmer Jakobsen et autres
Objective: In recent years randomized phase III clinical trials have attempted to improve first-line R-CHOP treatment of diffuse large B-cell lymphoma (DLBCL) through addition or substitution of drugs. Bortezomib treatment has shown significant clinical efficacy in other B-cell malignancies, and the REMoDL-B …
dk
(code pays fourni par la source)
2022
article
OpenAlex
Sunandini Sharma, Alyssa Bouska, Alicia Gamboa, Roshia Ali et autres
BACKGROUND Mantle Cell Lymphoma (MCL) is a B-cell lymphoma characterized by t(11;14) leading to CyclinD1 overexpression with highly variable clinical response. Although the tumor intrinsic mechanisms have been well studied and the role of the tumor microenvironment (TME) in survival and therapeutic …
us, dk
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Linnéa Schmidt, Issa Ismail Issa, Hulda Haraldsdóttir, Jonas Laugård Hald et autres
PURPOSE: Platinum-containing therapy is standard treatment for relapsed Diffuse Large B-Cell Lymphoma (DLBCL). However, the efficacy of treatment is limited by drug resistance leading to relapse. Cisplatin resistance has been linked to impairments of the DNA damage response, and several DNA repair …
dk
(code pays fourni par la source)
2020
article
OpenAlex
Lisa Greve Routhe, Ida Kristin Grimstad Andersen, Lissa V. Hauerslev, Issa Ismail Issa et autres
Abstract Neurodegeneration is associated with inflammation and mismanaged iron homeostasis, leading to increased concentration of non‐transferrin‐bound iron (NTBI) in the brain. NTBI can be taken up by cells expressing Zrt‐, Irt‐like protein‐14 (ZIP14), which is regulated by iron overload and pro‐inflammatory cytokines, …
dk
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Issa Ismail Issa, Rasmus Froberg Brøndum, Hanne Due, Linnéa Schmidt et autres
: Significant differences in predicted response to bendamustine were found in molecular subtypes of DLBCL and MM, encouraging validation in prospective bendamustine-treated cohorts with available gene expression profiles and follow-up data.
dk
(code pays fourni par la source)